New Blood Test Enhances Colorectal Cancer Recurrence Risk Prediction

Text
A new blood test developed by researchers at the University of California, San Francisco (UCSF) has shown improved accuracy in predicting the risk of colorectal cancer recurrence, according to a study published in Nature Cancer on July 20, 2026. The test uses machine learning to analyze metabolomic patterns in blood samples, identifying specific amino acids and DNA fragments linked to tumor metastasis.

The study, led by Dr. Emily Torres, a cancer biologist at UCSF, evaluated the test on 420 patients who had undergone surgery for early-stage colorectal cancer. Results showed the test correctly identified 89% of patients at high risk of recurrence, compared to 72% with standard clinical tools. The findings were validated in an independent cohort of 180 patients at Memorial Sloan Kettering Cancer Center in New York.

Methodology and Findings
The test works by detecting changes in metabolic profiles, particularly elevated levels of glycine and fluorine-containing compounds, which are associated with cancer cell proliferation. Researchers used liquid chromatography-mass spectrometry to measure these biomarkers and trained a machine learning model to distinguish between patients with varying recurrence risks.

"Traditional methods rely on tumor stage and genetic mutations, but this test adds a layer of metabolic insight," Torres said in a statement. "It’s like a fingerprint for how the cancer might behave after treatment." The study also found that patients with high-risk profiles had a 3.2 times greater likelihood of metastasis within three years, according to data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program.

Implications for Patient Care
The test could help clinicians tailor follow-up care, such as adjusting chemotherapy regimens or recommending more frequent imaging. For example, patients identified as high-risk might benefit from adjuvant therapies not typically used for early-stage disease.

Dr. Raj Patel, an oncologist at Johns Hopkins University not involved in the study, noted that the approach addresses a critical gap in colorectal cancer management. "Current tools often miss subtle biological changes that signal recurrence," he said. "This could reduce unnecessary treatments for low-risk patients while ensuring high-risk individuals receive timely interventions."

Challenges and Next Steps
While the test shows promise, researchers caution it is not yet ready for widespread clinical use. The study’s sample size was limited, and the technology requires specialized equipment not available in all hospitals. The team is now collaborating with the Food and Drug Administration (FDA) to design larger trials, with results expected by 2028.

The study also highlights the role of metabolomics in cancer research. Earlier this year, a separate team at the Dana-Farber Cancer Institute reported similar findings using a different metabolic profiling method, suggesting a growing interest in this field.

Public Health Context
Colorectal cancer is the second leading cause of cancer-related deaths in the U.S., with approximately 150,000 new cases diagnosed annually. Recurrence rates vary widely, and early detection remains a priority. The American Cancer Society recommends regular screenings starting at age 45, but the new test could complement these efforts by providing personalized risk assessments.

Researchers emphasize that the test should not replace existing diagnostic tools but serve as an adjunct. "It’s another piece of the puzzle," said Dr. Torres. "We’re still learning how to integrate these technologies into routine care."

As the field of precision oncology advances, tests like this one could transform how cancer is monitored and treated. For now, the focus remains on refining the technology and ensuring equitable access to such innovations.

Text
Subheading
Methodology and Findings
Text
The test works by detecting changes in metabolic profiles, particularly elevated levels of glycine and fluorine-containing compounds, which are associated with cancer cell proliferation. Researchers used liquid chromatography-mass spectrometry to measure these biomarkers and trained a machine learning model to distinguish between patients with varying recurrence risks.

"Traditional methods rely on tumor stage and genetic mutations, but this test adds a layer of metabolic insight," Torres said in a statement. "It’s like a fingerprint for how the cancer might behave after treatment." The study also found that patients with high-risk profiles had a 3.2 times greater likelihood of metastasis within three years, according to data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program.

Text
Subheading
Implications for Patient Care
Text
The test could help clinicians tailor follow-up care, such as adjusting chemotherapy regimens or recommending more frequent imaging. For example, patients identified as high-risk might benefit from adjuvant therapies not typically used for early-stage disease.

Dr. Raj Patel, an oncologist at Johns Hopkins University not involved in the study, noted that the approach addresses a critical gap in colorectal cancer management. "Current tools often miss subtle biological changes that signal recurrence," he said. "This could reduce unnecessary treatments for low-risk patients while ensuring high-risk individuals receive timely interventions."

Text
Subheading
Challenges and Next Steps
Text
While the test shows promise, researchers caution it is not yet ready for widespread clinical use. The study’s sample size was limited, and the technology requires specialized equipment not available in all hospitals. The team is now collaborating with the Food and Drug Administration (FDA) to design larger trials, with results expected by 2028.

The study also highlights the role of metabolomics in cancer research. Earlier this year, a separate team at the Dana-Farber Cancer Institute reported similar findings using a different metabolic profiling method, suggesting a growing interest in this field.

Text
Subheading
Public Health Context
Text
Colorectal cancer is the second leading cause of cancer-related deaths in the U.S., with approximately 150,000 new cases diagnosed annually. Recurrence rates vary widely, and early detection remains a priority. The American Cancer Society recommends regular screenings starting at age 45, but the new test could complement these efforts by providing personalized risk assessments.

Researchers emphasize that the test should not replace existing diagnostic tools but serve as an adjunct. "It’s another piece of the puzzle," said Dr. Torres. "We’re still learning how to integrate these technologies into routine care."

Text
Subheading
Looking Ahead
Text
As the field of precision oncology advances, tests like this one could transform how cancer is monitored and treated. For now, the focus remains on refining the technology and ensuring equitable access to such innovations.